Navigation Links
Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the Cowen & Co. Annual Health Care Conference
Date:2/28/2013

SAN DIEGO, Feb. 28, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Cowen & Co. Annual Health Care Conference in Boston. The presentation is scheduled for Monday, March 4, 2013 at 3:30 p.m. Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com.Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

WCG(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Orexigen Therapeutics to Present at Upcoming Investor Conferences
2. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
3. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
4. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
5. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
8. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
9. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
10. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
11. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... March 4, 2015 XBiotech announced today ... in patients with moderate to severe plaque psoriasis ... Phase II trial evaluated the potential benefit of ... targets interleukin-1 alpha (IL-1a). IL-1a is a pro-inflammatory ... in skin lesions. The Company claims that blockade ...
(Date:3/4/2015)... Kan. , March 4, 2015   Aratana ... pet therapeutics company focused on the licensing, development and ... announced that it will present at the Barclays ... 2015, at the Loews Miami Beach Hotel in ... Steven St. Peter , M.D., President and Chief Executive ...
(Date:3/4/2015)... 4, 2015 Following the reintroduction of ... Center (LAC) released a report today urging policymakers ... and heroin epidemic through more effective use of ... "The Case for Expanding Access to Medication-Assisted Treatment ... the health, justice, and economic advantages of medication-assisted ...
Breaking Medicine Technology:XBiotech Announces Phase II Psoriasis Study Results in JAMA Dermatology 2Aratana Therapeutics to Present at the Barclays Global Healthcare Conference 2Improved Medication-Assisted Treatment Policy Could Aid Epidemic of 20 Million Americans with Untreated Addiction 2
... Wash., Feb. 22, 2011 drugstore.com, inc. (Nasdaq: ... of health, beauty, clinical skincare, and vision products, ... at the following upcoming events with the financial ... Stanley Tech Media & Telecom Conference Date: February ...
... 2011 Express Scripts, Inc. (Nasdaq: ESRX ) announced ... 2011 Citi Global Healthcare Conference on March 3, 2011 at ... NY. 2011 Barclays Capital Global Healthcare Conference on March ... in Miami, FL These presentations will also be broadcast ...
Cached Medicine Technology:drugstore.com to Present at Upcoming Financial Conferences 2
(Date:3/4/2015)... March 04, 2015 Imagine No Malaria’s 2014 ... Care2 Innovator Award , an honor given to nonprofit ... at the Nonprofit Technology Conference (NTC15) in Austin, ... United Methodist Church in Austin, was on hand for the ... Imagine No Malaria. , Imagine No Malaria was one of ...
(Date:3/4/2015)... The Asia-Pacific phthalic anhydride market is estimated ... 2019, at a CAGR of 5.9% during the ... through the TOC of Asia-Pacific Phthalic Anhydride Market ... with the help of various tables and figures., ... a derivative of phthalic acid, which is either ...
(Date:3/4/2015)... When people talk about venues being the ... across numerous genres, the Houston Rodeo will be ... during the annual livestock show and rodeo, one popular band ... activities being held at the event. The 2015 show will ... will try and get the festival its largest attendance ever. ...
(Date:3/4/2015)... The federal litigation established for Lipitor ... caused patients to develop Type 2 diabetes continues to ... South Carolina. According to court documents, the proceeding’s next ... at 10:00 a.m. In advance of the Conference, the ... report to the Court by March 19, 2015. (In ...
(Date:3/4/2015)... FDA’s New Inspection Approach:, What Your ... 24, 2015 — 1:30 p.m. – 3:00 p.m. EDT, ... four hours of an inspection whether a manufacturer’s in ... “good” list, they’ll merely ask for reassurance that they ... the “bad” list, the manufacturer must get ready to ...
Breaking Medicine News(10 mins):Health News:Imagine No Malaria Receives Care2 Innovator Award 2Health News:Imagine No Malaria Receives Care2 Innovator Award 3Health News:The Asia-Pacific Ohthalic Anhydride Market is Estimated to Reach $5,632.8 Million by 2019 - A Report by MicroMarket Monitor 2Health News:The Asia-Pacific Ohthalic Anhydride Market is Estimated to Reach $5,632.8 Million by 2019 - A Report by MicroMarket Monitor 3Health News:Cheap Houston Rodeo Tickets: Ticket Down Slashes Houston Rodeo Tickets for John Legend, Pitbull, Alan Jackson, Tim McGraw, Zac Brown Band, Fall Out Boy & Miranda Lambert 2Health News:Cheap Houston Rodeo Tickets: Ticket Down Slashes Houston Rodeo Tickets for John Legend, Pitbull, Alan Jackson, Tim McGraw, Zac Brown Band, Fall Out Boy & Miranda Lambert 3Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 2Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 4
... a leader in the,DHA omega-3 food and supplements ... be expanding its reach in the animal feed,market ... DHA,Gold(R) product with Novus International, Inc. Martek will ... of its poultry and swine feed and,enrichment products. ...
... mortality could be reduced 20% for those awaiting new ... group-incompatible heart transplants can safely be performed in infants ... death rates among infants with heart problems, say U.S. ... reported to the United Network for Organ Sharing (UNOS)from ...
... doesn,t have excess stomach acid, study finds, , , MONDAY, ... anti-reflux medications to infants, new research suggests. , The ... given anti-reflux medications, which work by lowering levels of ... four out of five infants included in the study ...
... When lean healthy young adults gained about 9 pounds, ... -- but shedding the weight restored proper functioning, according ... important because this vessel disorder, known as endothelial dysfunction, ... the effects of modest weight gain on the disorder ...
... of Premium Term, NEW YORK, Nov. 5 ... and more convenient, AXA Equitable introduced today in,approved ... Return of,Premium Term (ROP Term(SM)) life insurance on ... with Simplified Issue makes buying life,insurance easier and ...
... World-renowned heart,surgeon Dr. Rafael Espada has made history by ... Alvaro Colom, with Dr.,Espada as his running mate, won ... the country,s votes. The two will take,office January 14, ... practiced for more than 30 years,as a heart surgeon ...
Cached Medicine News:Health News:Martek Signs Exclusive Worldwide Distributorship Agreement with Novus International 2Health News:Martek Signs Exclusive Worldwide Distributorship Agreement with Novus International 3Health News:Blood-Incompatible Heart Transplants Safe for Infants 2Health News:Anti-Reflux Drugs May Be Overprescribed in Infants 2Health News:Anti-Reflux Drugs May Be Overprescribed in Infants 3Health News:Modest gain in visceral fat causes dysfunction of blood vessel lining in lean, healthy humans 2Health News:Modest gain in visceral fat causes dysfunction of blood vessel lining in lean, healthy humans 3Health News:AXA Equitable Makes it Easier to Stop Ignoring Life Insurance 2Health News:AXA Equitable Makes it Easier to Stop Ignoring Life Insurance 3Health News:AXA Equitable Makes it Easier to Stop Ignoring Life Insurance 4Health News:Houston Heart Surgeon Elected Vice President of Guatemala 2
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
Steroid-eluting, screw-in pacing lead...
Tendril DX active-fixation leads allows for lower thresholds initially and during the lead maturation phase....
The Guidant Fineline II EZ Sterox with protective capsule is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
Medicine Products: